Skip to main content
. 2022 Feb 9;3(1):e118. doi: 10.1002/mco2.118

FIGURE 6.

FIGURE 6

Some essential considerations for disease‐driven design and development of the nanosystem‐based delivery of antitumor or anticancer agents (therapeutics), the aim has to be on the criteria for selecting the delivery system, drug, and target patient population. Reproduced with permission from Elsevier, 2017 148